Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04728633 · ClinicalTrials.gov registry record · Phase 2
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
A Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT04728633: Active Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver, sponsored by Thomas Jefferson University.
NCT04728633 is a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 28 participants, below the 131-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04728633, a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.
Primary Outcome
Response to treatment
Conditions Studied
Interventions
- OTHER Medical Device Usage and Evaluation
- DRUG Carmustine
- PROCEDURE Transarterial Chemoembolization
- DRUG Ethiodized Oil
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What the registry record for NCT04728633 still lists
NCT04728633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 131-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Medical Device Usage and Evaluation is the first listed.
NCT04728633 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04728633 about?
NCT04728633 is a clinical study titled "Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases". This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (ca...
What is the current status of trial NCT04728633?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-09-27. Estimated completion is 2027-06-30.
What conditions does trial NCT04728633 study?
This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8.
What interventions are being tested in trial NCT04728633?
The interventions under investigation include: Medical Device Usage and Evaluation (OTHER), Carmustine (DRUG), Transarterial Chemoembolization (PROCEDURE), Ethiodized Oil (DRUG).
Who is sponsoring clinical trial NCT04728633?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04728633 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04728633's enrollment target sits among peer trials
28 13th of 14 higher than 2 of 14 other Metastatic Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI